FDA clears light‑activated nerve‑repair polymer

The FDA has cleared a new way to reconnect severed peripheral nerves, and the novelty matters as much as the device itself. Tissium’s COAPTIUM CONNECT with TISSIUM LIGHT is not a better stitch. It is a different category of repair: a light-activated polymer and a small bioresorbable chamber that hold nerve ends together without microsutures, then gradually disappear as healing progresses (accessdata.fda.gov, tissium.com). That clearance came through the FDA’s De Novo pathway on June 17, 2025, which is what the agency uses when a device is novel enough that no existing regulatory box fits. The FDA created a new device type for it, “in situ polymerizing peripheral nerve repair device,” and placed it in Class II. That is the real signal here. The agency was not just allowing one product onto the market. It was acknowledging that nerve repair can now be done with a polymer that cures inside the body under light, instead of by passing tiny needles and sutures through fragile tissue (accessdata.fda.gov, accessdata.fda.gov). The target is peripheral nerve injuries, not the brain or spinal cord. These are the cut or torn nerves in hands, arms, legs, and other parts of the body that can leave people with numbness, weakness, or chronic pain. Standard repair usually means microsurgery under magnification, placing very fine sutures through the outer layer of the nerve to line up the ends. That works, but it also adds trauma at the very spot where regeneration has to begin. Reviews of the field still describe outcomes as inconsistent, even with modern microsurgery, because nerves regenerate slowly and scar easily (link.springer.com, mdpi.com). Tissium’s system is trying to remove that extra injury from the procedure. According to the FDA review, the device includes a single-use syringe filled with a photoactive polymer, an implantable 3D coaptation chamber, silicone accessories to position the nerve ends, and a separate light component used to activate the material. The indication is narrow: peripheral nerve injuries that are not in continuity, where the gap is 1 centimeter or less, or can be closed with flexion of the limb, and for nerves up to 6 millimeters in diameter. This is not a universal replacement for every nerve repair. It is a tool for a specific surgical problem that happens often enough to matter (accessdata.fda.gov). The evidence behind the clearance is promising, but still small. Tissium’s first-in-human study enrolled 12 patients with digital nerve injuries, with 10 completing one year of follow-up. The company says the procedures had 100 percent procedural success, and the Journal of Hand Surgery Global Online paper reports that the results support the concept of sutureless digital nerve repair as safe and effective in this setting. That is encouraging. It is not the same thing as proving superiority over sutures in a head-to-head trial, and the data do not yet do that (jhsgo.org, clinicaltrials.gov, tissium.com). Even so, the product moved quickly from clearance to use. Tissium announced a U.S. commercial launch on July 23, 2025, then reported the first commercial case in the United States in November 2025 at Cooper University Hospital in Camden, New Jersey. That sequence tells you this was not a lab curiosity waiting on years of rollout. It was a platform the company had been preparing to sell as soon as the FDA opened the door (tissium.com, tissium.com). The deeper story is that this device came out of a long-running biomaterials program, not a conventional implant business. Tissium was founded to commercialize work from labs at MIT and Brigham and Women’s Hospital, including research by Maria Pereira, Jeffrey Karp, and Robert Langer. The polymer was tuned to stick to wet tissue after blue-light activation, which is exactly the kind of materials problem that surgery has lived with for decades. Sutures are reliable because they are mechanical. Adhesives have usually failed because the body is wet, soft, and moving. This one got far enough to earn an FDA category of its own (news.mit.edu, cen.acs.org, tissium.com)